Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6184328rdf:typepubmed:Citationlld:pubmed
pubmed-article:6184328lifeskim:mentionsumls-concept:C0278996lld:lifeskim
pubmed-article:6184328lifeskim:mentionsumls-concept:C0445204lld:lifeskim
pubmed-article:6184328lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:6184328pubmed:issue1lld:pubmed
pubmed-article:6184328pubmed:dateCreated1983-2-14lld:pubmed
pubmed-article:6184328pubmed:abstractTextIn a prospective evaluation, two preoperative courses of methotrexate, bleomycin, and cisplatin combined with 2,000 rad/10 fractions ("chemo-radiotherapy") yielded 78% responses rates in previously untreated advanced head and neck cancer. Similarly staged patients receiving preoperative irradiation of 5,000 rad alone had a 67% response rate. Treatment-related mortality in the chemo-radiotherapy patients was equal to that seen with standard combinations of surgery and preoperative or postoperative irradiation. At 24 months, disease-free survival is 47% with chemo-radiotherapy vs 33% with standard therapy; however, patients benefiting most from the former approach were those with T4 primary lesions or N3a neck nodes.lld:pubmed
pubmed-article:6184328pubmed:languageenglld:pubmed
pubmed-article:6184328pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6184328pubmed:citationSubsetIMlld:pubmed
pubmed-article:6184328pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6184328pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6184328pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6184328pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6184328pubmed:statusMEDLINElld:pubmed
pubmed-article:6184328pubmed:issn0148-6403lld:pubmed
pubmed-article:6184328pubmed:authorpubmed-author:JohnsonF BFBlld:pubmed
pubmed-article:6184328pubmed:authorpubmed-author:MeyersA DADlld:pubmed
pubmed-article:6184328pubmed:authorpubmed-author:DiBellaN JNJlld:pubmed
pubmed-article:6184328pubmed:authorpubmed-author:PearlmanN WNWlld:pubmed
pubmed-article:6184328pubmed:issnTypePrintlld:pubmed
pubmed-article:6184328pubmed:volume5lld:pubmed
pubmed-article:6184328pubmed:ownerNLMlld:pubmed
pubmed-article:6184328pubmed:authorsCompleteYlld:pubmed
pubmed-article:6184328pubmed:pagination10-4lld:pubmed
pubmed-article:6184328pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6184328pubmed:meshHeadingpubmed-meshheading:6184328-...lld:pubmed
pubmed-article:6184328pubmed:meshHeadingpubmed-meshheading:6184328-...lld:pubmed
pubmed-article:6184328pubmed:meshHeadingpubmed-meshheading:6184328-...lld:pubmed
pubmed-article:6184328pubmed:meshHeadingpubmed-meshheading:6184328-...lld:pubmed
pubmed-article:6184328pubmed:meshHeadingpubmed-meshheading:6184328-...lld:pubmed
pubmed-article:6184328pubmed:meshHeadingpubmed-meshheading:6184328-...lld:pubmed
pubmed-article:6184328pubmed:meshHeadingpubmed-meshheading:6184328-...lld:pubmed
pubmed-article:6184328pubmed:meshHeadingpubmed-meshheading:6184328-...lld:pubmed
pubmed-article:6184328pubmed:meshHeadingpubmed-meshheading:6184328-...lld:pubmed
pubmed-article:6184328pubmed:meshHeadingpubmed-meshheading:6184328-...lld:pubmed
pubmed-article:6184328pubmed:meshHeadingpubmed-meshheading:6184328-...lld:pubmed
pubmed-article:6184328pubmed:meshHeadingpubmed-meshheading:6184328-...lld:pubmed
pubmed-article:6184328pubmed:meshHeadingpubmed-meshheading:6184328-...lld:pubmed
pubmed-article:6184328pubmed:meshHeadingpubmed-meshheading:6184328-...lld:pubmed
pubmed-article:6184328pubmed:meshHeadingpubmed-meshheading:6184328-...lld:pubmed
pubmed-article:6184328pubmed:meshHeadingpubmed-meshheading:6184328-...lld:pubmed
pubmed-article:6184328pubmed:articleTitlePreoperative chemo-radiotherapy in advanced head and neck cancer.lld:pubmed
pubmed-article:6184328pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6184328pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed